Aprogen Medicines (007460) Fundamentals 2026 — Revenue Analysis | SniperIQ
Aprogen Medicines (007460) is a KR-listed Industrials company in Industrial - Machinery with a market capitalization of ₩3.0B, trading at ₩2150.00 on the KSC. This SniperIQ fundamentals page covers Aprogen Medicines's valuation, profitability (net margin -56.9%), revenue (₩118.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Aprogen Medicines's market cap?
Aprogen Medicines (007460) has a market capitalization of approximately ₩3.0B, trading at ₩2150.00 on the KSC. Market cap moves with the live share price.
What is Aprogen Medicines's P/E ratio?
Aprogen Medicines's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Industrials sector peers rather than read in isolation.
How profitable is Aprogen Medicines?
Aprogen Medicines runs a net profit margin of -56.9%, a gross margin of 23.7%, and an operating margin of -75.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Aprogen Medicines generate?
Aprogen Medicines reported revenue of ₩118.0B for fiscal year 2025, with net income of -₩69.5B and earnings per share (EPS) of -52533.75. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Aprogen Medicines pay a dividend?
Aprogen Medicines does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Aprogen Medicines financially healthy?
Aprogen Medicines carries a debt-to-equity ratio of 1.33x and a current ratio of 0.85x, with a market beta of 0.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Aprogen Medicines a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Aprogen Medicines (007460) the key facts are: market cap ₩3.0B, revenue ₩118.0B, 52-week range 2100-14062.969. Weigh valuation, profitability, growth, and balance-sheet strength against Industrials peers and form your own view.
Track Aprogen Medicines's full fundamentals live
Get Aprogen Medicines's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.